The Development of Homologous (Canine/Anti-Canine) Antibodies in Dogs with Haemophilia A (Factor VIII Deficiency): A Ten-Year Longitudinal Study

Summary

The development of inhibitors to factor VIII in patients with haemophilia A remains as a serious complication of replacement therapy. An apparently analogous condition has been described in a canine model of haemophilia A (Giles et al., Blood 1984; 63:451). These animals and their relatives have now been followed for 10 years. The observation that the propensity for inhibitor development was not related to the ancestral factor VIII gene has been confirmed by the demonstration of vertical transmission through three generations of the segment of the family related to a normal (non-carrier) female that was introduced for breeding purposes. Haemophilic animals unrelated to this animal have not developed functionally significant factor VIII inhibitors despite intensive factor VIII replacement. Two animals have shown occasional laboratory evidence of factor VIII inhibition but this has not been translated into clinical significant inhibition in vivo as assessed by clinical response and F.VIII recovery and survival characteristics. Substantial heterogeneity of inhibitor expression both in vitro and in vivo has been observed between animals and in individual animals over time. Spontaneous loss of inhibitors has been observed without any therapies designed to induce tolerance, etc., being instituted. There is also phenotypic evidence of polyclonality of the immune response with variable expression over time in a given animal. These observations may have relevance to the human condition both in determining the pathogenetic factors involved in this condition and in highlighting the heterogeneity of its expression which suggests the need for caution in the interpretation of the outcome of interventions designed to modulate inhibitor activity.

• References

• 1 Bloom AL. The treatment of factor VIII inhibitors. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen R. et al. (eds) Leuven University Press; Leuven: 1987: 447-471
• 2 Rizza CR, Spooner RJD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: Report on behalf of the Directors of Haemophilia Centres in the United Kingdom. Br Med J 1983; 286: 929-933
• 3 Tuddenham EGD, Cooper DN, Gitschier J. et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor III gene. Nucl Acid Res 1991; 19: 4821-4833
• 4 Pattinson JK, Millar DS, McVey JH. et al. The molecular genetic analysis of hemophilia A: A directed search stategy for the detection of point mutations in the human factor VIII gene. Blood 1990; 76: 2242-2248
• 5 Giles AR, Tinlin S, Hoogendoorn H. et al. Development of factor VIII: C antibodies in dogs with hemophilia A (Factor VIII: C deficiency). Blood 1984; 63: 451-456
• 6 Brinkhous KM, Roberts HR, Weiss AE. Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh 1972; (Suppl. 51) 315-320
• 7 Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984; 150: 45-55
• 8 McMillan CW, Shapiro SS, Whitehurst D. et al. The natural history of factor VIII: C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 1988; 71: 344-348
• 9 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII: C deficiency) bleeding. Blood 1982; 60: 727-730
• 10 Kaper CK, Aledort LM, Counts RB. et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872
• 11 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemostas 1987; 58: 1078-1084
• 12 Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 1982; 52: 13-24
• 13 Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-950
• 14 Scandella D, Mattingly M, de Graaf S. et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626
• 15 Greenwood R. (Director of Animal Care Services, Queen’s University). Personal communication
• 16 Bloom AL. Progress in the clinical management of haemophilia. Thromb Haemostas 1991; 66 (01) 166-177